CA018-005 Kidney Cancer

Full Name

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)


The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer


Inclusion Criteria
  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with measurable disease
  • Life expectancy of at least 3 months
Exclusion Criteria
  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated
  • Patients/subjects with autoimmune disease
  • Patients/subjects who need daily oxygen therapy
  • Other protocol defined inclusion/exclusion criteria could apply
Doctor(s) Running This Study

Accepting New Patients

Hematology/Medical Oncology
Area of focus
Kidney cancer (renal cancer)
LVHN Affiliates
Lehigh Valley Cancer Institute

1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States

181 East Brown Street
East Stroudsburg, PA 18301-3004
United States

Make an Appointment
Need help scheduling? Contact Us